Last reviewed · How we verify
Acalabrutinib in combination with VR
BTK inhibitor
BTK inhibitor Used for Chronic lymphocytic leukemia (CLL).
At a glance
| Generic name | Acalabrutinib in combination with VR |
|---|---|
| Also known as | Acalabrutinib + VR |
| Sponsor | Acerta Pharma BV |
| Drug class | BTK inhibitor |
| Target | BTK |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Acalabrutinib is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), a key component in the B-cell receptor signaling complex.
Approved indications
- Chronic lymphocytic leukemia (CLL)
Common side effects
- Anemia
- Neutropenia
- Thrombocytopenia
- Anorexia
- Diarrhea
- Fatigue
- Nausea
- Vomiting
- Cough
- Dyspnea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acalabrutinib in combination with VR CI brief — competitive landscape report
- Acalabrutinib in combination with VR updates RSS · CI watch RSS
- Acerta Pharma BV portfolio CI